Clinical pharmacokinetics of 3-h extended infusion of meropenem in adult patients with severe sepsis and septic shock: implications for empirical therapy against Gram-negative bacteria

[1] Drusano GL(2003)Prevention of resistance: a goal for dose selection for antimicrobial agents Clin Infect Dis 36 S42-S50

[2] Gustafsson I(2001)Pharmacokinetic and pharmacodynamic parameters for antimicrobial effects of cefotaxime and amoxicillin in an in vitro kinetic model Antimicrob Agents Chemother 45 2436-2440

[3] Lowdin E(1995)Interrelationship between pharmacokinetics and pharmacodynamics in determining dosage regimens for broad-spectrum cephalosporins Diagn Microbiol Infect Dis 22 89-96

[4] Odenholt I(2011)Optimal treatment schedule of meropenem for adult patients with febrile neutropenia based on pharmacokinetic–pharmacodynamic analysis J Infect Chemother. 17 831-841

[5] Cars O(2011)Antibiotics in critically ill patients: a systematic review of the pharmacokinetics of beta-lactams Crit Care 15 R206-339

[6] Craig WA(2012)Clinical and microbiological efficacy of continuous versus intermittent application of meropenem in critically ill patients: a randomized open-label controlled trial Crit Care 16 R113-244

[7] Ohata Y(2010)Therapeutic drug monitoring of beta-lactams in critically ill patients: proof of concept Int J Antimicrob Agents 36 332-282

[8] Tomita Y(2013)Continuous infusion of beta-lactam antibiotics in severe sepsis: a multicenter double-blind, randomized controlled trial Clin Infect Dis 56 236-1339

[9] Nakayama M(2013)Clinical outcomes with extended or continuous versus short-term intravenous infusion of carbapenems and piperacillin/tazobactam: a systematic review and meta-analysis Clin Infect Dis 56 272-527

[10] Tamura K(2005)Comparison of the pharmacodynamics of meropenem in patients with ventilator-associated pneumonia following administration by 3-hour infusion or bolus injection Antimicrob Agents Chemother 49 1337-150

[1] Drusano GL(2003)Prevention of resistance: a goal for dose selection for antimicrobial agents Clin Infect Dis 36 S42-S50

[2] Gustafsson I(2001)Pharmacokinetic and pharmacodynamic parameters for antimicrobial effects of cefotaxime and amoxicillin in an in vitro kinetic model Antimicrob Agents Chemother 45 2436-2440

[3] Lowdin E(1995)Interrelationship between pharmacokinetics and pharmacodynamics in determining dosage regimens for broad-spectrum cephalosporins Diagn Microbiol Infect Dis 22 89-96

[4] Odenholt I(2011)Optimal treatment schedule of meropenem for adult patients with febrile neutropenia based on pharmacokinetic–pharmacodynamic analysis J Infect Chemother. 17 831-841

[5] Cars O(2011)Antibiotics in critically ill patients: a systematic review of the pharmacokinetics of beta-lactams Crit Care 15 R206-339

[6] Craig WA(2012)Clinical and microbiological efficacy of continuous versus intermittent application of meropenem in critically ill patients: a randomized open-label controlled trial Crit Care 16 R113-244

[7] Ohata Y(2010)Therapeutic drug monitoring of beta-lactams in critically ill patients: proof of concept Int J Antimicrob Agents 36 332-282

[8] Tomita Y(2013)Continuous infusion of beta-lactam antibiotics in severe sepsis: a multicenter double-blind, randomized controlled trial Clin Infect Dis 56 236-1339

[9] Nakayama M(2013)Clinical outcomes with extended or continuous versus short-term intravenous infusion of carbapenems and piperacillin/tazobactam: a systematic review and meta-analysis Clin Infect Dis 56 272-527

[10] Tamura K(2005)Comparison of the pharmacodynamics of meropenem in patients with ventilator-associated pneumonia following administration by 3-hour infusion or bolus injection Antimicrob Agents Chemother 49 1337-150